|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 4 (February 15), 2000:
pp. 1175-1179
Effect of recombinant human erythropoietin combined with
granulocyte/ macrophage colony-stimulating factor in the
treatment of patients with myelodysplastic syndrome
John A. Thompson,
D. Gary Gilliland,
Josef T. Prchal,
John M. Bennett,
Kay Larholt,
Richard A. Nelson,
Esther H. Rose,
Margaret H. Dugan, and
the GM/EPO MDS Study Group
From the Division of Oncology, University of Washington, Seattle,
WA; Hematology/Oncology Research, Howard Hughes Medical Institute,
Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
Division of Hematology/Oncology, University of Alabama, Birmingham, AL;
Cancer Center, University of Rochester, Rochester, NY; RW Johnson
Pharmaceutical Research Institute, Raritan, NJ; and Schering Plough
Research Institute, Kenilworth, NJ.
This randomized, placebo-controlled trial was designed to assess the
efficacy and safety of therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (epoetin alfa) in
anemic, neutropenic patients with myelodysplastic syndrome. Sixty-six
patients were enrolled according to the following
French-American-British classification: refractory anemia (20),
refractory anemia with excess blasts (35), refractory anemia with
ringed sideroblasts (9), and refractory anemia with excess blasts in
transformation (2). Patients were stratified by their serum
erythropoietin levels (less than or equal to 500 mU/mL, n = 37;
greater than 500 mU/mL, n = 29) and randomized, in a 2:1 ratio, to
either GM-CSF (0.3-5.0 µg/kg·d) + epoetin alfa (150 IU/kg 3 times/wk) or GM-CSF (0.3-5.0 µg/kg·d) + placebo (3 times/wk). The
mean neutrophil count rose from 948 to 3831 during treatment with
GM-CSF ± epoetin alfa. Hemoglobin response (increase greater than or
equal to 2 g/dL, unrelated to transfusion) occurred in 4 of 45 (9%)
patients in the GM-CSF + epoetin alfa group compared with 1 of 21 (5%) patients with GM-CSF + placebo group
(P = NS). Percentages of patients in the
epoetin alfa and the placebo groups requiring transfusions of red blood
cells were 60% and 92%, respectively, for the low-endogenous erythropoietin patients and 95% and 89% for the high-endogenous erythropoietin patients (P = NS). Similarly,
the average numbers of units of red blood cells transfused during the
12-week study in the epoetin alfa and the placebo groups were 5.9 and
9.5, respectively, in the low-endogenous erythropoietin patients and
9.7 and 8.6 in the high-endogenous erythropoietin patients
(P = NS). GM-CSF ± epoetin alfa had no
effect on mean platelet count. Treatment was well tolerated in most
patients, though 10 withdrew from the study for reasons related
predominantly to GM-CSF toxicity.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Dicato
Venous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update
Oncologist,
May 1, 2008;
13(suppl_3):
11 - 15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Ross, I. E. Allen, C. A. Probst, B. Sercus, S. M. Crean, and G. Ranganathan
Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
Oncologist,
October 1, 2007;
12(10):
1264 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, et al.
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.
J Natl Cancer Inst,
May 17, 2006;
98(10):
708 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Engert
Recombinant human erythropoietin in oncology: current status and further developments
Ann. Onc.,
October 1, 2005;
16(10):
1584 - 1595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bohlius, S. Langensiepen, G. Schwarzer, J. Seidenfeld, M. Piper, C. Bennett, and A. Engert
Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis
J Natl Cancer Inst,
April 6, 2005;
97(7):
489 - 498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Weiss and L. T. Goodnough
Anemia of Chronic Disease
N. Engl. J. Med.,
March 10, 2005;
352(10):
1011 - 1023.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Casadevall, P. Durieux, S. Dubois, F. Hemery, E. Lepage, M.-C. Quarre, G. Damaj, S. Giraudier, A. Guerci, G. Laurent, et al.
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial
Blood,
July 15, 2004;
104(2):
321 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Richard, M. Weinreich, K.-H. Chang, J. Ieremia, M. M. Stevenson, and C. A. Blau
Modulating erythrocyte chimerism in a mouse model of pyruvate kinase deficiency
Blood,
June 15, 2004;
103(12):
4432 - 4439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Moqattash and J. D. Lutton
Leukemia Cells and the Cytokine Network: Therapeutic Prospects
Experimental Biology and Medicine,
February 1, 2004;
229(2):
121 - 137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, P. Meyer, D. Dutt, F. Zorat, L. Lisak, F. Nascimben, M. du Randt, C. Kaspar, C. Goldberg, J. Loew, et al.
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
Blood,
August 15, 2001;
98(4):
958 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Goodnough, B. Skikne, and C. Brugnara
Erythropoietin, iron, and erythropoiesis
Blood,
August 1, 2000;
96(3):
823 - 833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hellstrom-Lindberg, C. Willman, A. J. Barrett, and Y. Saunthararajah
Achievements in Understanding and Treatment of Myelodysplastic Syndromes
Hematology,
January 1, 2000;
2000(1):
110 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
